drugset / Trial / NCT02384499

Treatment of Fecal Incontinence Using Allogenic-Adipose-derived Mesenchymal Stem Cells: A Prospective, Dose Escalation, Randomized, Placebo-controlled, Parallel-group, Single-blind, Single-center Pilot Study

NCT02384499

Phase 1 Completed 21 enrolled Yonsei University
RandomizedParallel-groupSingle-blindTreatment

Summary

* Purpose: The investigators aimed to investigate the safety and efficacy in the treatment of fecal incontinence by injection of ALLO-ASC into the anal sphincter. * Method 1. Safety test of allogenic ASCs injection 2. Efficacy test of allogenic ASCs injection

Timeline

Start
2014-12
Primary completion
2017-06-30
Completion
2017-06-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject ALLO-ASC Cell therapy 3e+07 unknown Other
Subject ALLO-ASC Cell therapy 6e+07 unknown Other
Subject ALLO-ASC Cell therapy 9e+07 unknown Other

Indications

No indication recorded.